XORTX Therapeutics Inc
XRTX
View Detailed Chart
0.560USD
-0.016-2.74%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
2.92MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.74%
5 Days
-4.22%
1 Month
-6.30%
6 Months
-30.14%
Year to Date
-50.40%
1 Year
-49.75%
View Detailed Chart
TradingKey Stock Score of XORTX Therapeutics Inc
Currency: USD Updated: 2025-10-27Key Insights
Its valuation is considered fairly valued, Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at max_target_price.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XORTX Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
14.000
Target Price
+2058.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
XORTX Therapeutics Inc Highlights
StrengthsRisks
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Fairly Valued
The company’s latest PE is -1.44, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 63.97K shares, decreasing 90.99% quarter-over-quarter.
XORTX Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
XORTX Therapeutics Inc Info
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Ticker SymbolXRTX
CompanyXORTX Therapeutics Inc
CEODavidoff (Allen W)
Websitehttps://www.xortx.com/
FAQs
What is the current price of XORTX Therapeutics Inc (XRTX)?
The current price of XORTX Therapeutics Inc (XRTX) is 0.560.
What is the symbol of XORTX Therapeutics Inc?
The ticker symbol of XORTX Therapeutics Inc is XRTX.
What is the 52-week high of XORTX Therapeutics Inc?
The 52-week high of XORTX Therapeutics Inc is 2.490.
What is the 52-week low of XORTX Therapeutics Inc?
The 52-week low of XORTX Therapeutics Inc is 0.700.
What is the market capitalization of XORTX Therapeutics Inc?
The market capitalization of XORTX Therapeutics Inc is 2.92M.
What is the net income of XORTX Therapeutics Inc?
The net income of XORTX Therapeutics Inc is -3.31M.
Is XORTX Therapeutics Inc (XRTX) currently rated as Buy, Hold, or Sell?
According to analysts, XORTX Therapeutics Inc (XRTX) has an overall rating of Buy, with a price target of 14.000.
What is the Earnings Per Share (EPS TTM) of XORTX Therapeutics Inc (XRTX)?
The Earnings Per Share (EPS TTM) of XORTX Therapeutics Inc (XRTX) is -0.400.
Related Instruments
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
